GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » Pre-Tax Income

Omega Therapeutics (Omega Therapeutics) Pre-Tax Income : $-92.28 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Omega Therapeutics's pretax income for the three months ended in Mar. 2024 was $-20.13 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-92.28 Mil. Omega Therapeutics's pretax margin was -852.92%.

During the past 5 years, Omega Therapeutics's highest Pretax Margin was -1868.35%. The lowest was -47416.67%. And the median was -4954.22%.


Omega Therapeutics Pre-Tax Income Historical Data

The historical data trend for Omega Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics Pre-Tax Income Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
-17.95 -29.45 -68.28 -102.70 -97.43

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.28 -29.69 -22.25 -20.21 -20.13

Competitive Comparison of Omega Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Omega Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omega Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's Pre-Tax Income falls into.



Omega Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Omega Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-100.261+0.023+0+2.81+0
=-97.43

Omega Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-20.451+-0.009+0+0.331+0
=-20.13

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omega Therapeutics  (NAS:OMGA) Pre-Tax Income Explanation

Omega Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-20.129/2.36
=-852.92%

During the past 5 years, Omega Therapeutics's highest Pretax Margin was -1868.35%. The lowest was -47416.67%. And the median was -4954.22%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omega Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Omega Therapeutics (Omega Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
20 Acorn Park Drive, Cambridge, MA, USA, 02140
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.
Executives
Michelle C Werner director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young director, 10 percent owner C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed officer: Chief Financial Officer C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus officer: Chief Human Resources Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng officer: See Remarks C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore officer: Chief Medical Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney officer: Chief Financial Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Omega Therapeutics (Omega Therapeutics) Headlines

From GuruFocus